Understanding heterogeneity in comparative effectiveness studies of natalizumab and fingolimod in multiple sclerosis: effect of analytical methodology - Département Méthodes quantitatives en santé publique Accéder directement au contenu
Article Dans Une Revue European Journal of Neurology Année : 2020

Understanding heterogeneity in comparative effectiveness studies of natalizumab and fingolimod in multiple sclerosis: effect of analytical methodology

Fichier non déposé

Dates et versions

hal-02887182 , version 1 (02-07-2020)

Identifiants

  • HAL Id : hal-02887182 , version 1

Citer

M. Lefort, S. Shannin, Jørgen Vitting Andersen, S. Vukusic, N. J. Koch-Henriksen, et al.. Understanding heterogeneity in comparative effectiveness studies of natalizumab and fingolimod in multiple sclerosis: effect of analytical methodology. European Journal of Neurology, 2020, 27, pp.342-342. ⟨hal-02887182⟩
58 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More